Skip to main content
Sona Nanotech Inc. logo

Sona Nanotech Inc. — Investor Relations & Filings

Ticker · SONA ISIN · CA83541C1059 CSE Professional, scientific and technical activities
Open in API
Filings indexed 424 across all filing types
Latest filing 2025-05-15 Regulatory Filings
Country CA Canada
Listing CSE SONA

About Sona Nanotech Inc.

https://www.sonanano.com/

Sona Nanotech Inc. is a life sciences company specializing in the development and commercialization of proprietary, uniquely biocompatible gold nanorod (GNR) technology. The primary therapeutic focus is Targeted Hyperthermia Therapy (THT), a photothermal cancer treatment utilizing GNRs to deliver precision heat directly to solid tumors. THT is designed to reduce tumor burden and stimulate immunogenic cell death while minimizing harm to healthy tissue. Sona is advancing THT through clinical trials for solid cancers, including melanoma. Furthermore, the company manufactures and supplies its patented, CTAB-free gold nanoparticles (nanorods and nanospheres) for integration into advanced materials science and medical diagnostic applications, such as lateral flow assays.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2025-05-15 English
News release - English.pdf
Regulatory Filings Classification · 75% confidence The document is a corporate press release announcing a research collaboration agreement between BioVaxys and Sona Nanotech. It contains forward-looking statements, company descriptions, and details of the collaboration, but it is not an earnings release, management report, financing update, M&A announcement, vote result, regulatory rate notice, or any other specific filing type. It does not present financial statements itself nor announce publication of a formal report. Therefore, it falls into the fallback category of general regulatory/press announcements (RNS).
2025-05-07 English
News release - English.pdf
Share Issue/Capital Change Classification · 85% confidence The document is a press release announcing annual incentive stock option grants under the Company’s Stock Option Plan, including the number of options, vesting schedule, exercise price, and expiry. This constitutes a change in the company’s capital structure via potential future share issuance under its option plan. It is not an earnings release, management discussion, or regulatory proxy statement, so the most appropriate category is Share Issue/Capital Change (SHA).
2025-05-01 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 80% confidence The provided text is a Form 52-109FV2 “Venture Issuer Basic Certificate” certifying the review and fair presentation of the interim financial statements and MD&A for an interim period. It is not the interim report itself (it contains no financial statements or MD&A details), but a compliance certificate required under Canadian NI 52-109. This does not fit categories like IR (interim report), MDA (management discussion and analysis), or an announcement of a report; rather, it represents a regulatory compliance filing. Therefore, it should be classified under the fallback “Regulatory Filings” (RNS).
2025-03-31 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 80% confidence The document is a Form 52-109 FV2 “Venture Issuer Basic Certificate” certifying the interim financial statements and interim MD&A for the period ended January 31, 2025, under Canadian NI 52-109. This is not the interim report itself (IR) nor an announcement of its release (RPA), but a regulatory certification form accompanying filings. It therefore falls under the general “Regulatory Filings” fallback category (RNS).
2025-03-31 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Unaudited Condensed Interim Consolidated Financial Statements' for Sona Nanotech Inc. for the quarters ended January 31, 2025 and 2024. It contains comprehensive financial statements (Statement of Financial Position, Statement of Loss and Comprehensive Loss, Statement of Changes in Equity, Statement of Cash Flows) and detailed explanatory notes. This meets the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2025
2025-03-31 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.